MoonLake Immunotherapeutics MLTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -77.7%-17.2pp | -60.5%-6.3pp | -54.2%-13.9pp | -40.3%-9.7pp | -30.6%-5.3pp | |
| Return on invested capital | -199.6%-44.1pp | -155.5%+198pp | -353.1%-221pp | -132.2%-18.1pp | -114.1%-23.9pp | |
| Liquidity | ||||||
| Current ratio | 8.6×-0.7× | 9.3×+0.8× | 8.5×-8.1× | 16.6×-4.5× | 21.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.1× | 0.2×0.0× | 0.3×0.0× | 0.2×0.0× | 0.2×+0.2× | |
| Per Share | ||||||
| Book value per share | $3.56-24.5% | $4.72+3.6% | $4.56-18.4% | $5.59-13.3% | $6.44-9.3% | |
| Valuation | ||||||
| Market capitalization | $1.34B+43.2% | $933.77M+105% | $455.31M-84.3% | $2.9B+17.5% | $2.47B-27.6% | |
| Price / book | 5.3×+2.2× | 3.1×+1.5× | 1.6×-6.6× | 8.2×+2.1× | 6.1×-1.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do MoonLake Immunotherapeutics's ratios come from?
- Every ratio is computed from MoonLake Immunotherapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.